Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
GT Biopharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
GTBP
Nasdaq
2834
https://www.gtbiopharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for GT Biopharma Inc
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
- Mar 26th, 2024 9:00 pm
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
- Feb 1st, 2024 4:00 pm
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders
- Dec 6th, 2023 2:30 pm
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
- Dec 4th, 2023 2:30 pm
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
- Nov 6th, 2023 2:30 pm
GT Biopharma Reports Third Quarter 2023 Financial Results
- Nov 1st, 2023 1:00 pm
GT Biopharma Reports Second Quarter 2023 Financial Results
- Aug 7th, 2023 1:00 pm
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023
- Aug 3rd, 2023 5:25 pm
GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
- May 15th, 2023 9:00 pm
GT Biopharma Names Charles J. Casamento to the Board of Directors
- May 4th, 2023 1:05 pm
GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
- Mar 30th, 2023 9:00 pm
Scroll